In all three groups, the percent change in BCVA and CMT was found to be significant on months 6, 9, 12 and 24 when compared to baseline (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Purpose: To evaluate the changes in best corrected visual acuity (BCVA) and central macular thickness (CMT) in patients who received intravitreal dexamethasone implant (DEX-implant) and anti-vascular endothelial growth factor (VEGF) in the treatment of macular edema secondary Branch Retinal Vein Occlusion (BRVO).
📊
Key Findings & Data:Materials and Methods: In this interventional, retrospective, single-center study, BCVA and CMT at baseline and on months 6, 9, 12 and 24 as well as mean number of injections and adverse effects were evaluated in 91 eyes with macular edema secondary to BRVO which were treated via intravitreal route.
💡
Conclusion & Impact:In all three groups, the percent change in BCVA and CMT was found to be significant on months 6, 9, 12 and 24 when compared to baseline (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Purpose: To evaluate the changes in best corrected visual acuity (BCVA) and central macular thickness (CMT) in patients who received intravitreal dexamethasone implant (DEX-implant) and anti-vascular endothelial growth factor (VEGF) in the treatment of macular edema secondary Branch Retinal Vein Occlusion (BRVO). Materials and Methods: In this interventional, retrospective, single-center study, BCVA and CMT at baseline and on months 6, 9, 12 and 24 as well as mean number of injections and adverse effects were evaluated in 91 eyes with macular edema secondary to BRVO which were treated via intravitreal route. Results: In our study, 24 patients received intravitreal DEX-implant (group 1) and 46 patients received intravitreal anti-VEGF (group 2). The treatment was switched in 21 patients who were resistant to treatment (group 3). The mean number of injections was 2.13 (± 1.2) in group 1, 4 (± 1.8) in group 2 and 5.6 (± 3) in group 3. In all three groups, the percent change in BCVA and CMT was found to be significant on months 6, 9, 12 and 24 when compared to baseline (p
🔖
Cite This Article
ULUTAŞ, H. G., BALIKÇI, A., ASLANCI, M. E. (2022). Results of Intravitreal Dexamethasone Implant and Anti-VEGF Treatment in Treatment of Macular Edema Secondary to Branch Retinal vein Occlusion. Retina-Vitreus, Cilt: 30 - Sayı: 3, 245–252. https://ajindex.com/articles/589063
Jaulim A, Ahmed B, Chatziralli IP. Branch retinal vein occlusion:epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 2013;33:901-10
Son BK, Kwak HW, Kim ES, et al. Comparison of ranibizumab and bevacizumab for macular edema associated with branch retinal vein occlusion. Korean J Ophthalmol 2017;31:209-16
Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010; 117: 1094-101.e5 4. Regnier SA, Larsen M, Bezlyak V, et al. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network metaanalysis. BMJ Open 2015; 5: e007527
Campochiaro PA, Heier JS, Feiner L, et al, BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102-12
Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology.2012; 119: 1175-83
Tadayoni R, Waldstein SM, Boscia F,et al.; BRIGHTER Study Group: Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER Study. Ophthalmology 124: 1778-87, 2017
Wei W, Weisberger A, Zhu L,et al.; BLOSSOM Study Group. Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study. Ophthalmol Retina. 2020; 4: 57-66. doi: 10.1016/j.oret.2019.08.001. Epub 2019 Aug 13. PMID: 31902472
Campochiaro PA, Clark WL, Boyer DS, Heier JS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT Study. Ophthalmology. 2015; 122: 538-44. doi:10.1016/j. ophtha.2014.08.031
ClarkWL, Boyer DS, Heier JS,et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT Study. Ophthalmology.2016; 123: 330- 6
Haller J, Bandello F, Belfort R Jr, et al, OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-46
Brown DM, Campochiaro PA, Singh RP, et al, CRUISE Investigators. Ranibizumab for